This week, the Computer and Personal Electronics, Energy Services, Computer and Personal Electronics, Oil and Gas, and Marine sectors look weak according to Portfolio Grader.
With 78% of its stocks (74 out of 95) rated “sell,” the Metals and Mining sector is struggling this week. Out of the Metals and Mining stocks, Cliffs Natural Resources (NYSE:), Walter Energy (NYSE:), and Thompson Creek Metals Company Inc. (NYSE:) are near the bottom with F’s. Over the last 12 months, Walter Energy is the worst performer in this sector, with a 74.6% decline.
Hot Valued Stocks To Invest In 2015: Ormat Technologies Inc.(ORA)
Ormat Technologies, Inc., together with its subsidiaries, engages in the geothermal and recovered energy power business in the United States and internationally. The company operates in two segments, Electricity and Product. The Electricity segment develops, builds, owns, and operates geothermal and recovered energy-based power plants; and sells the electricity. The Product segment designs, manufactures, and sells power units for geothermal and recovered energy-based electricity generation; fossil fuel powered turbo-generators; and heavy duty direct-current generators. It also provides services relating to the engineering, procurement, construction, operation, and maintenance of geothermal and recovered energy power plants. This segment serves contractors and geothermal power plant owners and operators; and interstate natural gas pipeline owners and operators, gas processing plant owners and operators, cement plant owners and operators, and companies in other energy-intens ive industrial processes. The company was founded in 1965 and is based in Reno, Nevada. Ormat Technologies, Inc. is a subsidiary of Ormat Industries Ltd.
Advisors' Opinion:- [By Jonathan Morgan]
Orange SA (ORA), the phone company formerly known as France Telecom, retreated 3.9 percent to 9.75 euros as Bouygues SA unveiled a new Internet and calls package for 15.99 euros a month. The price is ��articularly aggressive,��Jacques de Greling, an analyst at Natixis SA, wrote in a report.
- [By Marie Mawad]
Orange SA (ORA), France�� biggest phone company, agreed to sell its Dominican Republic unit to Altice, a cable and telecommunications investor, for $1.4 billion.
- [By Seth Jayson]
Ormat Technologies (NYSE: ORA ) reported earnings on May 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Ormat Technologies met expectations on revenues and beat expectations on earnings per share. - [By John Udovich]
Yesterday, small cap geothermal stock U.S. Geothermal Inc (NYSEMKT: HTM) produced a geyser of a return when it surged 26.79%, meaning its worth taking a closer look at the stock verses the performance of other geothermal stocks like small cap Ormat Technologies, Inc (NYSE: ORA) and mid cap Calpine Corporation (NYSE: CPN).�First of all, I should mention there are some other geothermal stocks out there like Alterra Power Corp (CVE: AXY) and Ram Power Corp (TSE: RPG) who have their primary listing on Canadian exchanges with secondary ones on the OTC���meaning they may not be a good deal for American investors or easy to invest in. Second, U.S. Geothermal Inc itself is a good geothermal proxy as its�focused on developing, owning, and operating clean, sustainable electric power from geothermal energy resources and its�operating geothermal power projects at Neal Hot Springs, Oregon; San Emidio, Nevada; and Raft River, Idaho plus El Ceibillo, an advanced stage, geothermal prospect located within a 24,710 acre energy rights concession area near Guatemala City, the largest city in Central America.
Top 5 Building Product Companies To Watch In Right Now: ZIOPHARM Oncology Inc(ZIOP)
ZIOPHARM Oncology, Inc., a biopharmaceutical company, engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company's clinical programs include Palifosfamide, a DNA cross-linker, which is in a phase III clinical trial for the treatment of metastatic soft tissue sarcoma in the front-line setting. ZIOPHARM is also developing Palifosfamide in combination with etoposide and carboplatin in phase I clinical trial to determine safety for initiating a pivotal, adaptive phase III trial in front-line. In addition, the company, in partnership with Intrexon Corporation, is developing DNA-based therapeutics (synthetic biology) that include two phase 1 clinical-stage product candidates, both of which are DNA IL-12 to be turned on/off by an oral activator ligand. Further, it is developing Indibulin, an oral tubulin binding agent, which is in Phase 1/2 for metastatic breast cancer; and Darinaparsin , a mitochondrial- and hedgehog-targeted agent that is in a solid tumor phase I study with oral administration and has been developed intravenously for the treatment of relapsed peripheral T-cell lymphoma. The company was founded in 2003 and is headquartered in New York City, New York.
Advisors' Opinion:- [By James E. Brumley]
Four months ago, you could barely give your shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) away. The company announced s on Tuesday, March 26th, that its sarcoma drug Palifosfamide had failed to meet its Phase 3 goals. Shares of ZIOP plunged from $5.13 to $1.82 in a mere day, and were trading as low as $1.51 a week and a half later.
- [By James E. Brumley]
Back on July 16th, I pointed out ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) was a budding superstar. Though I suggested waiting for the stock to cool off before stepping into it (and it did cool off, by the way), ZIOP has since walked its way above the key line in the sand that was acting like a ceiling then. Though there's still one more hurdle shares need to clear before being a "must-have" stock, the heavy lifting's been done.
- [By Garrett Cook]
In trading on Tuesday, healthcare shares were relative laggards, down on the day by about 0.14 percent. Top losers in the sector included ZIOPHARM Oncology (NASDAQ: ZIOP), down 8.9 percent, and Sanofi (NYSE: SNY), off 9.3 percent.
- [By John Udovich]
Biotech in general has been one of the market�� hottest sectors this year thanks to plenty of mostly good news�along with�new IPOs while small cap biotech stocks Delcath Systems (NASDAQ: DCTH), ZIOPHARM Oncology Inc (NASDAQ: ZIOP), Recro Pharma (NASDAQ: REPH), TetraLogic Pharmaceuticals (NASDAQ: TLOG)�and TNI BioTech (OTCMKTS: TNIB) have also produced their share of news�this week or in recent weeks. Just consider the following:
Top 5 Building Product Companies To Watch In Right Now: Sonde Resources Corp (SOQ)
Sonde Resources Corp. (Sonde) is engaged in the exploration for, and acquisition, development and production of, petroleum and natural gas with operations in Western Canada and North Africa. On June 23, 2011, the Company sold its interests in Block 5(c) and the assumption of certain liabilities in respect of the MG Block through the Niko Sale Agreement. On September 23, 2011, the Company acquired a block of producing and non-producing assets in Drumheller from a third party, which includes the bulk of producing interests in the Mannville I oil pool. On January 1, 2012, the Company amalgamated Seeker Petroleum Ltd., Challenger Energy Corp. and Sonde Resources Trinidad and Tobago Ltd. into Sonde Resources Corp. On February 8, 2012, the Company completed the sale of 26,240 gross undeveloped acres (24,383 net acres) in its Kaybob Duvernay play in Alberta. Advisors' Opinion:- [By John Udovich]
While Bakken formation oil and gas stocks have grabbed the attention of�American investors, small cap Alberta or Saskatchewan oil and gas stocks Advantage Oil & Gas Ltd (NYSE: AAV), Sonde Resources Corp (NYSEMKT: SOQ) and up and coming Centor Energy Inc (OTCBB: CNTO) have been largely overlooked as they seek to exploit oil and gas (including oil sands) in the resource rich Canadian provinces of Alberta or Saskatchewan or seek strategic alternatives for their assets in these areas or themselves. It should be mentioned that Canada�� oil reserves are third only to Venezuela and Saudi Arabia with over 95% of these reserves being the oil sands of Alberta plus that province contains much of the country�� conventional oil reserves as well. In addition, the province of Saskatchewan along with offshore areas of Newfoundland contain substantial production and reserves. Excluding oil sands, Alberta would have 39% of Canada�� remaining conventional oil reserves,�followed by�offshore Newfoundland with�28% and Saskatchewan with 27%.
Top 5 Building Product Companies To Watch In Right Now: ChemoCentryx Inc (CCXI)
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�� wholly owned subsidiary is ChemoCentryx Limited.
The Company's drug candidate Traficet-EN (CCX282, GSK'786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Company has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company�� Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK).
The Company's independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of th! e immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.
CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of rheumatoid arthritis (RA) patients contains high levels of activated CCR1 chemokine ligands. The Company completed two Phase I clinical trials in a total of 84 healthy subjects, conducted in Switzerland followed by a Phase I/II clinical trial in 24 patients with stable RA, conducted in Belgium and Romania, and a Phase II proof-of-concept clinical trial in 160 patients with moderate-to-severe RA, conducted in Belgium, the Czech Republic, Germany, Hungary, Poland, Romania and the Ukraine. GSK exercised its option to further develop and commercialize CCX354 in November 2011 and had an exclusive right to initiate a Phase II b clinical trial for CCX354 in RA.
CCX168 targets the chemo-attractant C5a receptor (C5aR), which binds to a biologically activated fragment of the complement protein known as C5. As of December 31, the Company completed a Phase I clinical trial for CCX168, conducted in Switzerland. The Company initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011. Its CCX872 is an independent next generation CCR2 drug candidate for the treatment of metabolic diseases, its CCX507 is an independent drug candidate for the treatment of inflammatory bowel disease (IBD) and CCX662 is an independent drug candidate for the treatment of glioblastoma multiforme (GBM).
The Company competes with Abbott Laboratories, Amgen Inc, AstraZeneca plc, Biogen Idec Inc, Bayer AG, Elan Corporation plc, Glaxo Group Limited, Merck & Co Inc, Merck Serono, Takeda Pharmaceutical Co Ltd, Novartis AG! , Pfizer ! Inc, Reata Pharmaceuticals, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Incyte Corp and UCB Pharma.
Advisors' Opinion:- [By James E. Brumley]
The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that plagued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.